NYSE:CRY - CryoLife Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.00
  • Forecasted Upside:
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New CryoLife Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRY

Analyst Price Target is $32.00
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for CryoLife in the last 3 months. The average price target is $32.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for CRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in CryoLife. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/7/2022Morgan StanleyLower Price TargetEqual Weight$29.00 ➝ $25.00High
7/30/2021Morgan StanleyBoost Price TargetEqual Weight$31.00 ➝ $32.00Medium
7/30/2021Needham & Company LLCBoost Price TargetBuy$38.00 ➝ $39.00High
7/15/2021Morgan StanleyInitiated CoverageEqual Weight$31.00High
5/6/2021Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $38.00High
4/30/2021Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $38.00High
2/12/2021Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $33.00Low
11/5/2020Needham & Company LLCLower Price TargetBuy$29.00 ➝ $28.00High
9/3/2020Needham & Company LLCReiterated RatingBuy$29.00High
9/2/2020OppenheimerReiterated RatingBuy$25.00High
7/30/2020OppenheimerReiterated RatingBuy$25.00Medium
6/30/2020Needham & Company LLCInitiated CoverageBuy$29.00Low
5/1/2020Lake Street CapitalBoost Price TargetBuy$22.00 ➝ $27.00Medium
4/3/2020Lake Street CapitalReiterated RatingBuy$38.00 ➝ $22.00High
4/2/2020OppenheimerLower Price Target$34.00 ➝ $25.00Low
4/2/2020Needham & Company LLCLower Price TargetBuy$38.00 ➝ $29.00Low
2/14/2020Needham & Company LLCReiterated RatingBuy$38.00Medium
2/14/2020First AnalysisDowngradeStrong-Buy ➝ OutperformHigh
1/29/2020Needham & Company LLCBoost Price TargetBuy$30.00 ➝ $38.00Low
12/11/2019Needham & Company LLCUpgradeHold ➝ Buy$30.00High
10/22/2019OppenheimerInitiated CoverageOutperform$34.00Low
5/12/2019Needham & Company LLCReiterated RatingHoldHigh
5/1/2019Needham & Company LLCReiterated RatingHoldHigh
2/27/2019Needham & Company LLCInitiated CoverageHold ➝ Hold$29.65Low
1/17/2019Northland SecuritiesReiterated RatingBuy$32.00Low
8/7/2018Northland SecuritiesReiterated RatingBuy$32.00High
3/8/2018Northland SecuritiesReiterated RatingBuy$23.50High
11/13/2017Northland SecuritiesReiterated RatingBuy$23.50N/A
10/11/2017Lake Street CapitalBoost Price TargetBuy$26.00N/A
(Data available from 5/22/2017 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 5 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
CryoLife logo
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $19.05
Low: $17.19
High: $21.72

52 Week Range

Now: N/A

Volume

7,792 shs

Average Volume

198,221 shs

Market Capitalization

$703.22 million

P/E Ratio

596.20

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of CryoLife?

The following Wall Street sell-side analysts have issued reports on CryoLife in the last twelve months: Morgan Stanley, Needham & Company LLC, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for CRY.

What is the current price target for CryoLife?

0 Wall Street analysts have set twelve-month price targets for CryoLife in the last year. Their average twelve-month price target is $32.00.
View the latest price targets for CRY.

What is the current consensus analyst rating for CryoLife?

CryoLife currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRY will outperform the market and that investors should add to their positions of CryoLife.
View the latest ratings for CRY.

How do I contact CryoLife's investor relations team?

CryoLife's physical mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider's listed phone number is (770) 419-3355 and its investor relations email address is [email protected] The official website for CryoLife is www.cryolife.com. Learn More about contacing CryoLife investor relations.